Use of competitive progesterone antagonists - to inhibit development of endometrial glands essential for implantation of eggs in the uterus

摘要

Use of competitive progesterone antagonists is claimed for inhibitor of development of endometrial glands whose function allows implentation of fertilised eggs in the uterus. a dosage unit is given in the follicular follicle (prior to ovulation) and in the lateral phase (after ovulation). The dosage is not sufficient to inhibit ovulation or act as an abortifacient. USE/ADVANTAGE - The process gives an excellent contraceptive effect, even for women with an irregular menstrual cycle. Admin. is local, topical, enteral, transdermal or parenteral, esp. oral, in doses of 0.25-20 mg. Application is every 4-10 days, beginning at any time prior to ovulation. Treatment does not affect the length of the menstrual cycle.